Apixaban and vascular health in atrial fibrillation study (AVAS)
Research type
Research Study
Full title
Apixaban and vascular health in atrial fibrillation study (AVAS)
IRAS ID
236868
Contact name
Gregory Lip
Contact email
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Atrial fibrillation is the most common sustained heart rhythm disorder. Atrial fibrillation is associated with substantial risk of severe stroke, cognitive decline and dementia. Research is required to better understand the reasons for this and to develop effective countermeasures.
We have recently identified vascular damage/ dysfunction in atrial fibrillation, indicated by elevated plasma biomarkers and impairments in conduit (brachial). A complex interplay between inflammation, coagulation and vascular function exists in atrial fibrillation, with emerging evidence supporting the concept that anticoagulant proteins (e.g., factor Xa) can modulate cytokine-release and thus promote endothelial vascular damage/ dysfunction in atrial fibrillation. Therefore, we seek to determine whether treatment with a non-Vitamin K antagonist oral anticoagulant (NOAC), specifically the oral direct factor Xa inhibitor apixaban, enhances systemic and cerebral vascular function in atrial fibrillation.
These investigations will provide important new mechanistic insights into the elevated risk of cerebrovascular events in atrial fibrillation and the therapeutic benefits of apixaban.
REC name
North West - Preston Research Ethics Committee
REC reference
17/NW/0714
Date of REC Opinion
12 Dec 2017
REC opinion
Further Information Favourable Opinion